{"url_path":"/sec/cmps/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1816590/0001816590-26-000042-index.html","accession_number":"0001816590-26-000042","cik":"0001816590","ticker":"CMPS","issuer_name":"COMPASS Pathways plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1816590/0001816590-26-000042-index.html","primary_entity_key":"0001816590","primary_entity_name":"COMPASS Pathways plc"},"word_count":2990,"has_tables":true,"body_markdown":"cmps-20260331\n00018165902026Q1FALSE12-3155xbrli:sharesiso4217:USDiso4217:GBPxbrli:sharesiso4217:USDxbrli:sharesxbrli:purecmps:installmentcmps:daycmps:segment00018165902026-01-012026-03-3100018165902026-05-0600018165902026-03-3100018165902025-12-3100018165902025-01-012025-03-310001816590cmps:OrdinarySharesMember2026-03-310001816590cmps:OrdinarySharesMember2025-12-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2024-12-310001816590us-gaap:AdditionalPaidInCapitalMember2024-12-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001816590us-gaap:RetainedEarningsMember2024-12-3100018165902024-12-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2025-01-012025-03-310001816590us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001816590us-gaap:RetainedEarningsMember2025-01-012025-03-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2025-03-310001816590us-gaap:AdditionalPaidInCapitalMember2025-03-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001816590us-gaap:RetainedEarningsMember2025-03-3100018165902025-03-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2025-12-310001816590us-gaap:AdditionalPaidInCapitalMember2025-12-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001816590us-gaap:RetainedEarningsMember2025-12-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2026-01-012026-03-310001816590us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001816590us-gaap:RetainedEarningsMember2026-01-012026-03-310001816590cmps:OrdinarySharesMemberus-gaap:CommonStockMember2026-03-310001816590us-gaap:AdditionalPaidInCapitalMember2026-03-310001816590us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001816590us-gaap:RetainedEarningsMember2026-03-310001816590cmps:ADSWarrantsMember2026-01-012026-03-310001816590cmps:ADSWarrantsMember2025-01-012025-03-310001816590cmps:PrefundedWarrantsMember2026-01-012026-03-310001816590cmps:PrefundedWarrantsMember2025-01-012025-03-310001816590cmps:AmericanDepositarySharesMemberus-gaap:IPOMember2021-10-0800018165902021-10-082021-10-080001816590cmps:AtTheMarketOfferingMember2021-10-092025-02-270001816590cmps:AmericanDepositarySharesMembercmps:AtTheMarketOfferingMember2025-02-270001816590cmps:LoanAgreementMember2023-06-300001816590cmps:LoanAgreementTermLoanOneMember2023-06-300001816590cmps:AmendedLoanAgreementMember2026-01-052026-01-050001816590cmps:AmendedLoanAgreementMember2026-01-050001816590cmps:LoanAgreementTermLoanOneMember2026-01-050001816590us-gaap:PrivatePlacementMember2023-08-162023-08-160001816590us-gaap:PrivatePlacementMember2023-08-160001816590cmps:PIPEWarrantsMemberus-gaap:PrivatePlacementMember2024-02-290001816590cmps:PIPEWarrantsMember2026-01-012026-03-310001816590cmps:PIPEWarrantsMember2025-01-012025-03-310001816590cmps:PIPEWarrantsMember2023-08-172026-03-310001816590cmps:A2025ADSWarrantsMembercmps:UnderwrittenOfferingMember2025-01-012025-01-310001816590cmps:A2025ADSWarrantsMembercmps:UnderwrittenOfferingMember2025-01-310001816590cmps:PrefundedWarrantsMembercmps:UnderwrittenOfferingMember2025-01-310001816590cmps:A2025ADSWarrantsMembercmps:UnderwrittenOfferingMember2026-02-012026-02-280001816590cmps:UnderwrittenOfferingMember2026-02-012026-02-280001816590cmps:PrefundedWarrantsMembercmps:UnderwrittenOfferingMember2026-02-280001816590cmps:A2026ADSWarrantsMembercmps:UnderwrittenOfferingMember2026-02-192026-02-190001816590cmps:A2026ADSWarrantsMembercmps:UnderwrittenOfferingMember2026-02-190001816590cmps:PrefundedWarrantsMembercmps:UnderwrittenOfferingMember2026-02-190001816590cmps:UnderwrittenOfferingMember2026-02-192026-02-190001816590us-gaap:FairValueInputsLevel1Member2026-03-310001816590us-gaap:FairValueInputsLevel2Member2026-03-310001816590us-gaap:FairValueInputsLevel3Member2026-03-310001816590us-gaap:FairValueInputsLevel1Member2025-12-310001816590us-gaap:FairValueInputsLevel2Member2025-12-310001816590us-gaap:FairValueInputsLevel3Member2025-12-3100018165902023-12-310001816590cmps:AmendedLoanAgreementTermLoanOneMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2026-01-050001816590cmps:AmendedLoanAgreementTermLoanOneMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2026-01-050001816590cmps:AmendedLoanAgreementTermLoanOneMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2026-01-050001816590cmps:AmendedLoanAgreementTermLoanOneMemberus-gaap:DebtInstrumentRedemptionPeriodFourMember2026-01-050001816590cmps:AmendedLoanAgreementTermLoanOneMemberus-gaap:DebtInstrumentRedemptionPeriodFiveMember2026-01-050001816590cmps:AmendedLoanAgreementTermLoanOneMember2026-01-050001816590cmps:LoanAgreementMember2026-01-050001816590cmps:LoanAgreementMember2026-01-052026-01-050001816590cmps:LoanAgreementMember2026-03-310001816590cmps:LoanAgreementMembercmps:FacilityFeesMember2026-03-310001816590cmps:LoanAgreementMembercmps:CompanyFeesMember2026-03-310001816590cmps:LoanAgreementMembercmps:WarrantFeesMember2026-03-310001816590cmps:LoanAgreementMembercmps:EndOfTermChargeMember2026-03-310001816590cmps:AmendedLoanAgreementMember2026-03-310001816590cmps:AmendedLoanAgreementMembercmps:FacilityFeesMember2026-03-310001816590cmps:AmendedLoanAgreementMembercmps:EndOfTermChargeMember2026-03-3100018165902023-06-300001816590cmps:PrefundedWarrantsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001816590cmps:PrefundedWarrantsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001816590cmps:A2025ADSWarrantsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001816590cmps:A2025ADSWarrantsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001816590cmps:PrefundedWarrantsMember2025-12-310001816590cmps:A2025ADSWarrantsMember2025-12-310001816590cmps:A2025ADSWarrantsMember2026-01-012026-03-310001816590cmps:PrefundedWarrantsMember2026-03-310001816590cmps:A2025ADSWarrantsMember2026-03-310001816590cmps:HerculesCapitalInc.Member2023-06-300001816590us-gaap:PrivatePlacementMember2023-08-182023-08-1800018165902023-08-182023-08-180001816590cmps:PIPEWarrantsMemberus-gaap:PrivatePlacementMember2023-08-180001816590cmps:PIPEWarrantsMember2026-03-310001816590cmps:A2025ADSWarrantsMembercmps:UnderwrittenOfferingMember2025-01-132025-01-130001816590cmps:A2025ADSWarrantsMember2025-01-132025-01-130001816590cmps:A2025ADSWarrantsMembercmps:UnderwrittenOfferingMember2026-02-280001816590cmps:PrefundedWarrantsMembercmps:UnderwrittenOfferingMember2026-03-310001816590cmps:A2017EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2026-03-310001816590us-gaap:EmployeeStockMember2026-03-310001816590us-gaap:EmployeeStockMember2026-01-012026-03-310001816590cmps:A2020ShareOptionPlanMembercmps:OrdinarySharesMember2026-03-310001816590cmps:A2020ShareOptionPlanMembercmps:OrdinarySharesMember2022-01-010001816590cmps:A2020ShareOptionPlanMember2026-03-310001816590cmps:A2022InducementGrantOptionAwardMembercmps:OrdinarySharesMember2022-12-310001816590cmps:A2026InducementPlanMembercmps:OrdinarySharesMember2026-03-310001816590us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001816590us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001816590us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001816590us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001816590cmps:EmployeeSharePurchasePlanMember2026-01-012026-03-310001816590cmps:EmployeeSharePurchasePlanMember2025-01-012025-03-310001816590cmps:UnvestedRestrictedShareUnitsMember2026-01-012026-03-310001816590cmps:UnvestedRestrictedShareUnitsMember2025-01-012025-03-310001816590cmps:ShareOptionsMember2026-01-012026-03-310001816590cmps:ShareOptionsMember2025-01-012025-03-310001816590cmps:EquityWarrantsMember2026-01-012026-03-310001816590cmps:EquityWarrantsMember2025-01-012025-03-310001816590cmps:LiabilityWarrantsMember2026-01-012026-03-310001816590cmps:LiabilityWarrantsMember2025-01-012025-03-310001816590cmps:DevelopmentExpensesMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:DevelopmentExpensesMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:PersonnelExpensesMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:PersonnelExpensesMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:NonCashShareBasedCompensationExpenseMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:NonCashShareBasedCompensationExpenseMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:OtherExpensesMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:OtherExpensesMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:LegalAndProfessionalFeesMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:LegalAndProfessionalFeesMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:FacilitiesAndOtherExpensesMembercmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:FacilitiesAndOtherExpensesMembercmps:SingleOperatingSegmentMember2025-01-012025-03-310001816590cmps:SingleOperatingSegmentMember2026-01-012026-03-310001816590cmps:SingleOperatingSegmentMember2025-01-012025-03-31\n\n      \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nForm 10-Q\n\n⊠ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ________ to ________\n\nCommission File Number: 001-39522\n\nCOMPASS Pathways plc\n\n(Exact name of registrant as specified in its charter)\n\nEngland and WalesNot Applicable\n\n(State or other jurisdiction of\nincorporation or organization)(I.R.S. Employer\nIdentification No.)\n\n33 Broadwick Street\n\nLondon W1F 0DQ\n\nUnited Kingdom\n\n(Address of principal executive offices, zip code)\n\n+1 (716) 676-6461\n\n(Registrant’s telephone number, including area code)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of Each Class Trading Symbol Name of each exchange on which registered\n\nAmerican Depositary Shares, each representing one ordinary share, par value of £0.008 per share\n \nCMPS\n \nNasdaq Global Select Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer☐Accelerated filer ☐\n\nNon-accelerated filer☒Smaller reporting company☒\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nThe registrant had 134,949,320 shares of common stock outstanding as of May 6, 2026.\n\nTABLE OF CONTENTS\n\n[PART I - FINANCIAL INFORMATION](#id77189ab689c4864a2a8ead06224a2c6_16)\n\n[Item 1.](#id77189ab689c4864a2a8ead06224a2c6_19)\n\n[Financial Statements (Unaudited)](#id77189ab689c4864a2a8ead06224a2c6_19)\n\n[8](#id77189ab689c4864a2a8ead06224a2c6_19)\n\nCondensed Consolidated Balance Sheets As of March 31, 2026 and March 31, 2025\n\n[8](#id77189ab689c4864a2a8ead06224a2c6_25)\n\nCondensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2026 and 2025\n\n[9](#id77189ab689c4864a2a8ead06224a2c6_28)\n\nCondensed Consolidated Statements of Shareholders’ Equity (Deficit) for the Three Months ended March 31, 2026 and 2025\n\n[10](#id77189ab689c4864a2a8ead06224a2c6_31)\n\nCondensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2026 and 2025\n\n[11](#id77189ab689c4864a2a8ead06224a2c6_34)\n\n[Notes to Condensed Consolidated Financial Statements](#id77189ab689c4864a2a8ead06224a2c6_37)\n\n[12](#id77189ab689c4864a2a8ead06224a2c6_37)\n\n[Item 2.](#id77189ab689c4864a2a8ead06224a2c6_79)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#id77189ab689c4864a2a8ead06224a2c6_79)\n\n[29](#id77189ab689c4864a2a8ead06224a2c6_79)\n\n[Item 3.](#id77189ab689c4864a2a8ead06224a2c6_100)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#id77189ab689c4864a2a8ead06224a2c6_100)\n\n[36](#id77189ab689c4864a2a8ead06224a2c6_100)\n\n[Item 4.](#id77189ab689c4864a2a8ead06224a2c6_103)\n\n[Controls and Procedures](#id77189ab689c4864a2a8ead06224a2c6_103)\n\n[36](#id77189ab689c4864a2a8ead06224a2c6_103)\n\n[PART II - OTHER INFORMATION](#id77189ab689c4864a2a8ead06224a2c6_106)\n\n[Item 1.](#id77189ab689c4864a2a8ead06224a2c6_109)\n\n[Legal Proceedings](#id77189ab689c4864a2a8ead06224a2c6_109)\n\n[37](#id77189ab689c4864a2a8ead06224a2c6_109)\n\n[Item 1A.](#id77189ab689c4864a2a8ead06224a2c6_512)\n\n[Risk Factors](#id77189ab689c4864a2a8ead06224a2c6_512)\n\n[37](#id77189ab689c4864a2a8ead06224a2c6_512)\n\n[Item 2.](#id77189ab689c4864a2a8ead06224a2c6_115)\n\n[Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](#id77189ab689c4864a2a8ead06224a2c6_115)\n\n[175](#id77189ab689c4864a2a8ead06224a2c6_115)\n\n[Item 3.](#id77189ab689c4864a2a8ead06224a2c6_118)\n\n[Defaults Upon Senior Securities](#id77189ab689c4864a2a8ead06224a2c6_118)\n\n[175](#id77189ab689c4864a2a8ead06224a2c6_118)\n\n[Item 4.](#id77189ab689c4864a2a8ead06224a2c6_121)\n\n[Mine Safety Disclosures](#id77189ab689c4864a2a8ead06224a2c6_121)\n\n[175](#id77189ab689c4864a2a8ead06224a2c6_121)\n\n[Item 5.](#id77189ab689c4864a2a8ead06224a2c6_124)\n\n[Other Information](#id77189ab689c4864a2a8ead06224a2c6_124)\n\n[175](#id77189ab689c4864a2a8ead06224a2c6_124)\n\n[Item 6.](#id77189ab689c4864a2a8ead06224a2c6_127)\n\n[Exhibits](#id77189ab689c4864a2a8ead06224a2c6_127)\n\n[176](#id77189ab689c4864a2a8ead06224a2c6_127)\n\n[Signatures](#id77189ab689c4864a2a8ead06224a2c6_130)\n\n[177](#id77189ab689c4864a2a8ead06224a2c6_130)\n\n2\n\nTable of Contents\n\nSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the “Securities Act,” and Section 21E of the Securities Exchange Act of 1934, as amended, or the “Exchange Act”. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions. The forward-looking statements and opinions contained in this Form 10-Q are based upon information available to our management as of the date of this Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:\n\n•the timing, progress and results of our Phase 3 program for treatment-resistant depression, or TRD, and our other clinical trials of investigational COMP360 psilocybin treatment, including statements regarding the preliminary results to date from our two ongoing Phase 3 trials for TRD, the timing of initiation and completion of trials or studies and related preparatory work, our expectations regarding the periods during which the 26-week results of our second Phase 3 trial for TRD will become available, and our expectations regarding the timing of our rolling submission of a new drug application, or NDA, for COMP360 psilocybin treatment in TRD and the timing of the review by the Food and Drug Administration, or FDA, of such NDA, including potential acceleration due to the grant of rolling review and award of a Commissioner’s National Priority Voucher, or CNPV, for COMP360 psilocybin treatment in TRD;\n\n•the timing, progress and results of our Phase2b/3 clinical trial in post-traumatic stress disorder, or PTSD, including statements regarding our trial designs and our expectations regarding discussions with the FDA, including discussions regarding our trial design;\n\n•our estimates regarding our expenses, capital requirements, the sufficiency of our cash resources and our expected cash runway;\n\n•our reliance on the success of our investigational COMP360 psilocybin treatment;\n\n•our expectations regarding the size of the eligible patient populations for COMP360 psilocybin treatment, if approved for commercial use;\n\n•our ability to identify third-party clinical sites to conduct our trials and our ability to identify and train appropriately qualified healthcare professionals to monitor and safeguard participants receiving COMP360 psilocybin treatment in our clinical trials;\n\n•our ability to implement our business model and our strategic plans for our business and our investigational COMP360 psilocybin treatment;\n\n•our ability to identify new indications for COMP360 beyond our current primary focus on TRD and PTSD;\n\n•our commercialization, marketing and manufacturing capabilities and strategy, including our ability to accelerate our commercial launch planning;\n\n3\n\nTable of Contents\n\n•the pricing, coverage and reimbursement of our investigational COMP360 psilocybin treatment, if approved;\n\n•the scalability and commercial viability of our manufacturing methods and processes, including our ability to add commercial manufacturing capacity in the U.S.;\n\n•the rate and degree of market acceptance and clinical utility of our investigational COMP360 psilocybin treatment, in particular, and psilocybin-based treatments, in general;\n\n•our ability to raise additional capital or secure other financing to fund our operations;\n\n•the potential for outstanding warrants to purchase American Depositary Shares, or ADSs, to be exercised in full for cash and any expected proceeds from the exercise of our outstanding warrants;\n\n•our ability to establish or maintain collaborations or strategic relationships;\n\n•our expectations regarding potential benefits of our investigational COMP360 psilocybin treatment and our treatment approach generally;\n\n•our expectations around feedback from, and discussions with regulators regarding regulatory development paths and Controlled Substances Act designation, each of which may be subject to potential impacts of regulatory agency staffing cuts and policy changes on regulatory feedback and timing thereof;\n\n•the scope of protection we and any current or future licensors or collaboration partners are able to establish and maintain for intellectual property rights covering COMP360;\n\n•our ability to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties;\n\n•our ability to identify, maintain, utilize, acquire or purchase digital technologies to enhance the administration of our investigational COMP360 psilocybin treatment in the conduct of our clinical trials;\n\n•regulatory developments in the United States, or U.S., under the laws and regulations of England and Wales, and other jurisdictions;\n\n•developments and projections relating to our competitors and our industry;\n\n•the effectiveness of our internal control over financial reporting;\n\n•our ability to attract and retain qualified employees and key personnel, including our ability to grow our commercial team;\n\n•our ability to achieve specified regulatory and commercial milestones, and in the case of the final tranche to secure approval from lenders’ investment committees, to draw down additional amounts up to $100.0 million in accordance with the terms of our Loan and Security Agreement, as amended by the third amendment dated January 5, 2026, or the Loan Agreement, with Hercules Capital, Inc., or Hercules, and our ability to comply with the operating and financial covenants, including the minimum cash covenant, in our Loan Agreement;\n\n•the effect of global financial and economic conditions and geopolitical events, including fluctuating interest rates and inflation, foreign exchange fluctuations (particularly the Pound Sterling to U.S. Dollar), the risk of an economic slowdown or recession in the U.S., instability in the banking system, overall market volatility in the U.S. or the UK, including as a result of, among other factors, geopolitical conflict (such as, the war between Russia and Ukraine and conflict in the Middle East), international tensions or instability (including from the effects of announced or future\n\n4\n\nTable of Contents\n\ntariff increases), significant changes in U.S. policies or regulatory environment or the disruption to U.S. government agencies or similar events, on our business;\n\n•the effect of public health crises, pandemics or epidemics and any future mitigation efforts, and current or future economic effects, on any of the foregoing or other aspects of our business or operations;\n\n•whether we are classified as a controlled foreign corporation, or CFC, or a passive foreign investment company, or PFIC, under the Internal Revenue Code of 1986, as amended, for current and future periods; and\n\n•the future trading price of the ADSs and impact of securities analysts’ reports on these prices.\n\nWe caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.\n\nYou should not rely upon forward-looking statements as predictions of future events, which speak only as of the date made. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in the section titled “Risk Factors” in Part II, Item 1A, of this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as otherwise required by law, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. \n\nReferences to “we,” “our,” “us” and “the Company” refer to Compass Pathways plc.\n\n5\n\nTable of Contents\n\nSUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS\n\nOur business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:\n\n•We are a clinical-stage biotechnology company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability;\n\n•Unless and until we generate product revenue and achieve and sustain profitability, we will continue to need additional financing to fund our operations and capital expenditures. Failure to obtain additional funding when needed or on favorable terms may force us to delay, limit or terminate certain or all of our product discovery, therapeutic development, research operations or commercialization efforts or grant rights to develop and market products or therapeutic candidates;\n\n•Raising additional capital through the sale of equity or convertible securities or the cash exercise of outstanding warrants may cause significant dilution to holders of our ordinary shares and ADSs, and raising additional capital through debt financings, strategic partnerships, collaborations, or other means may restrict our operations or require us to relinquish rights to therapeutic candidates intellectual property rights of third parties could adversely affect our ability to develop or commercialize our investigational treatments, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our investigational treatments. Such litigation or licenses could be costly or not available on commercially reasonable terms;\n\n•Our operating activities may be restricted as a result of covenants related to our Loan Agreement, which could have a material adverse effect on our business, financial condition, and results of operations;\n\n•COMP360 psilocybin treatment is, and any future therapeutic candidates we may develop may be, subject to controlled substance laws and regulations in the jurisdictions where our products, if approved, may be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, or changes in these laws and regulations may adversely affect the results of our business operations, both during clinical development and post approval, and our financial condition;\n\n•Adverse publicity or public perception regarding psilocybin or our current or future investigational treatments using psilocybin, or regarding other controlled substances, may negatively influence the success of these treatments;\n\n•We are dependent on the successful development of our investigational COMP360 psilocybin treatment. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes;\n\n•COMP360 and any future therapeutic candidates we may develop may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval or adversely affect the commercial profile for the treatment;\n\n•Research and development of drugs targeting the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive effect on some patients but not others;\n\n•We have never commercialized a therapeutic candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our treatments on our own or with suitable collaborators or on an accelerated timeline;\n\n•The future commercial success of our investigational COMP360 psilocybin treatment will depend on the degree of market access and acceptance of our potential treatments;\n\n6\n\nTable of Contents\n\n•Our business and commercialization strategy for our investigational COMP360 psilocybin treatment depends on our ability to identify, qualify, prepare, and support third-party treatment sites. If we are unable to do so, our commercialization prospects would be limited and our business would be harmed;\n\n•In our clinical trials, we currently rely on specially trained, licensed healthcare professionals working at third-party clinical trial sites and upon regulatory approval we expect to continue to rely on healthcare professionals working at third-party sites, to monitor and safeguard participants during administration of our COMP360 psilocybin treatment. If third-party sites fail to recruit, retain or effectively manage a sufficient number of qualified healthcare professionals, our clinical trials may be delayed and our business, financial condition and results of operations would be materially harmed;\n\n•Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects;\n\n•Recently enacted and future legislation or changes in regulatory conditions may increase the difficulty and cost for us to obtain marketing approval of, adequate reimbursement for and commercialize our investigational COMP360 psilocybin treatment;\n\n•We rely on third parties to supply drug substances and manufacture, package and distribute COMP360 for our clinical trials, and, if approved, we will continue to rely on third parties for commercial supply. If any third-party provider fails to meet its obligations to supply drug substance or manufacture COMP360, or fails to maintain or achieve satisfactory regulatory compliance, the development of such substance and the commercialization of any treatments, if approved, could be stopped, delayed or made commercially unviable, or less profitable or may result in enforcement actions against us;\n\n•There are a number of third parties who conduct investigator-initiated studies, or IISs, using COMP360 provided by us. IISs of COMP360 may generate clinical trial data that raises concerns regarding the safety or effectiveness of COMP360;\n\n•We face substantial competition and our competitors may discover, develop or commercialize treatments before or more successfully than us, which may result in the reduction or elimination of our commercial opportunities;\n\n•We may face business interruptions, data loss, unauthorized access to or disclosure of personal health information or other personally identifiable information, failures or significant downtime of our information technology systems, negative publicity or reputational damage resulting from cyber-attacks on our systems or other cybersecurity incidents or data breaches; and\n\n•Unfavorable global economic and geopolitical conditions as well as volatility in the financial markets have in the past and could in the future adversely affect our business, financial condition or results of operations.\n\n7\n\nTable of Contents\n\nPART I—FINANCIAL INFORMATION"}